<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32653</article-id><article-id pub-id-type="doi">10.17116/terarkh2016886105-113</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Chronic hepatitis C virus infection: An internist’s opinion (Part 1)</article-title><trans-title-group xml:lang="ru"><trans-title>Хроническая HCV-инфекция: взгляд интерниста (I часть)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zubkin</surname><given-names>M L</given-names></name><name xml:lang="ru"><surname>Зубкин</surname><given-names>М Л</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chervinko</surname><given-names>V I</given-names></name><name xml:lang="ru"><surname>Червинко</surname><given-names>В И</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ovchinnikov</surname><given-names>Yu V</given-names></name><name xml:lang="ru"><surname>Овчинников</surname><given-names>Ю В</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kryukov</surname><given-names>E V</given-names></name><name xml:lang="ru"><surname>Крюков</surname><given-names>Е В</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kotenko</surname><given-names>O N</given-names></name><name xml:lang="ru"><surname>Котенко</surname><given-names>О Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Московский НИИ эпидемиологии и микробиологии им. Г.Н. Габричевского Роспотребнадзора</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="ru">Филиал Военно-медицинской академии им. С.М. Кирова, Москва</institution></aff><aff><institution xml:lang="en"></institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="ru">Филиал Военно-медицинской академии им. С.М. Кирова</institution></aff><aff><institution xml:lang="en"></institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="ru">Главный военный клинический госпиталь им. Н.Н. Бурденко</institution></aff><aff><institution xml:lang="en"></institution></aff></aff-alternatives><aff id="aff5"><institution>Городская клиническая больница №52 Департамента здравоохранения Москвы</institution></aff><pub-date date-type="pub" iso-8601-date="2016-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2016</year></pub-date><volume>88</volume><issue>10</issue><issue-title xml:lang="en">VOL 88, NO10 (2016)</issue-title><issue-title xml:lang="ru">ТОМ 88, №10 (2016)</issue-title><fpage>105</fpage><lpage>113</lpage><history><date date-type="received" iso-8601-date="2020-04-11"><day>11</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/32653">https://ter-arkhiv.ru/0040-3660/article/view/32653</self-uri><abstract xml:lang="en"><p>Hepatitis C virus (HCV) infection results in not only chronic hepatitis and subsequent complications as liver cirrhosis and hepatocellular carcinoma, but also in a significant number of other diseases, the so-called extrahepatic manifestations of chronic HCV infection. This is because of viral hepatotropicity and lymphotropicity. The most striking example of the course of chronic HCV infection, in which the infectious and inflammatory processes are concurrent with autoimmune disorders and carcinogenesis, is mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma. The pathogenesis of these diseases is based on the clonal expansion of B cells, which occurs under their prolonged stimulation with the virus or viral proteins. Part 1 of this review is devoted to the analysis of a correlation of chronic HCV infection with lymphoproliferative and autoimmune disorders, as well as its association with kidney injury.</p></abstract><trans-abstract xml:lang="ru"><p>Аннотация Инфицирование вирусом гепатита С (HCV) приводит к развитию не только хронического гепатита с последующими осложнениями в виде цирроза печени и гепатоцеллюлярной карциномы, но и значительного числа других заболеваний — так называемых внепеченочных проявлений хронической HCV-инфекции. Это объясняется как гепато-, так и лимфотропностью вируса. Наиболее ярким примером такого течения хронической HCV-инфекции, при котором происходит сочетание инфекционно-воспалительного процесса с аутоиммунными расстройствами и онкогенезом, служат смешанная криоглобулинемия и В-клеточная не-Ходжкинская лимфома. В основе патогенеза этих патологических состояний лежит клональная экспансия В-лимфоцитов, возникающая в условиях их продолжительной стимуляции вирусом или вирусными белками. Первая часть настоящего обзора посвящена анализу связи хронической HCV-инфекции с развитием лимфопролиферативных и аутоиммунных расстройств, а также ассоциации с поражением почек.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic hepatitis C virus infection</kwd><kwd>extrahepatic manifestations</kwd><kwd>direct-acting antiviral agents</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая HCV-инфекция</kwd><kwd>внепеченочные проявления</kwd><kwd>препараты прямого противовирусного действия</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis. 1990;162(2):569-570. doi:10.1093/infdis/162.2.569</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Zignego AL, Giannini C, Monti M, Gragnani L. Hepatitis C virus lymphotropism: lessons from a decade of studies. Digestive Liver Dis. 2007;39(1):38-45. doi: 10.1016/S1590-8658(07)80009-0</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, Michalak TI. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology. 2008;134(3):812-822. doi:10.1053/j.gastro.2007.12.011</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, Antonelli A, Zignego AL. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol. 2015;7(3):327-343. doi:10.4254/wjh.v7.i3.327</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Reviews in basic and clinical gastroenterology and hepatology. Gastroenterology. 2015;49(6):1345-1360. doi:10.1053/j.gastro.2015.08.035</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Zignego AL, Gragnani L, Piluso А, Sebastiani M, Giuggioli D, Fallahi P, Antonelli A., Ferri C. Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol. 2015;11(1):15-31. doi:10.1586/1744666X.2015.997214</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ferri C., Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, Zignego AL. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Digestive Liver Dis. 2007;39(1):13-21. doi: 10.1016/S1590-8658(07)80005-3</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469-477. doi:10.1093/infdis/jis385</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Maruyama S, Koda Ma, Oyake N, Sato H, Fujii Y,Horie Y, Murawaki Y. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol. 2013;58(1):11-15. doi:10.1016/j.jhep.2012.07.045</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Brouet JC, Clauvel JP, Danon F, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775-788. doi:10.1016/0002-9343(74)90852-3</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Terrier B, Karras A, Kahn JE, Le Guenno G, Marie I, Benarous L, Lacraz A, Diot E, Hermine O, de Saint-Martin L, Cathébras P, Leblond V, Modiano P, Léger JM, Mariette X, Senet P, Plaisier E, Saadoun D, Cacoub P. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore) 2013;92(2):61-68. doi:10.1097/MD.0b013e318288925c</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ghetie D, Mehraban N, Sibley CH. Cold hard facts of cryoglobulinemia: updates on clinical features and treatment advances. Rheum Dis Clin North America. 2015;41(1):93-108. doi:10.1016/j.rdc.2014.09.008</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Saadoun D, Thibault V, Si Ahmed SN, Alric LMallet M, Guillaud C, Izzedine H, Plaisier A, Fontaine H, Costopoulos MLe Garff-Tavernier M, Hezode C, Pol S, Musset L, Poynard T, Cacoub P. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2015;0:1-6. doi:10.1136/annrheumdis-2015-208339</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Dammacco F, Racanelli V, Russi S, Sansonno D. The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review. Clin Exper Med. 2016;1-10. doi:10.1007/s10238-016-0410-9</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. New Engl J Med. 2013; 369(11):1035-1045. doi:10.1056/NEJMra1208642</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sansonno D, Gesualdo L, Manno C, Schena FP, Dammacco F. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology. 1997;25(5):1237-1244. doi:10.1002/hep.510250529</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Mariotto S, Ferrari S, Monaco S. HCV-related central and peripheral nervous system demyelinating disorders. Inflammation Allergy Drug Targets. 2014;13:299-304. doi:10.2174/1871528113666140908113841</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Gupta A, Quigg RJ. Glomerular Diseases Associated With Hepatitis B and C. Advances Chron Kidney Dis. 2015;22(5):343-351. doi:10.1053/j.ackd.2015.06.003</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Barsoum RS. Hepatitis C virus: from entry to renal injury — facts and potentials. Nephrol Dial Transplant. 2007;22(7):1840-1848. doi:10.1093/ndt/gfm205</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia — a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med. 1966;40(6):837-856. doi:10.1016/0002-9343(66)90200-2</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Retamozo S, Diaz-Lagares C, Bosch X, Bove A, Brito-Zeron P, Gomez ME, Yagüe J, Forns X, Cid MC, Ramos-Casals M. Lifethreatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine (Baltimore). 2013;92(5):273-284. doi:10.1097/MD.0b013e3182a5cf71</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia Vasculitis.Am J Med. 2015;128(9):950-955. doi:10.1016/j.amjmed.2015.02.017</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8(12):1017-1029. doi:10.1016/j.cgh.2010.08.026</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>МухинН.А., КозловскаяЛ.В., МалышкоЕ.Ю. Криоглобулинемическийнефрит, ассоциированныйсхроническойинфекциейвирусагепатитаС. Терапевтическийархив. 2000;6:1-5.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Tampaki M, Koskinas J. Extrahepatic immune related manifestations in chronic hepatitis C virus infection. World J Gastroenterol. 2014:20(35):12372-12380. doi:10.3748/wjg.v20.i35.12372</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>КозловскаяЛ.В, ТэгайС.В., МалышкоЕ.Ю., ЛопаткинаТ.Н., КосминковаЕ.Н. Поражениепочек, ассоциированноесвирусамигепатитовВиС. Consilium Med. 2002;4(7):337-341.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Лысенко Л.В., Гордовская Н.Б., Коротчаева Ю.В. «Диагностика и лечение нефрита при HBV и HCV инфекции, включая нефрит при криоглобулинемическом васкулите». Национальные клинические рекомендации по лечению гломерулонефритов. Под редакцией Шилова Е.М. Сборник клинических рекомендаций. М.: Белыйветер; 2015.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Fabrizi F, Martin P, Cacoub P, Messa P, Donato FM. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother. 2015;16(12):1815-1827. doi:10.1517/14656566.2015.1066333</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Ferri C, Antonelli A, Sebastiani M, Colaci M, Zignego AL. The expanding spectrum of clinical features in HCV-related mixed cryoglobulinemia. In: Dammacco F, editor. HCV infection and cryoglobulinemia. Milan: Springer-Verlag Italia; 2012.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Милованова С.Ю., Козловская Л.В., Гордовская К.Б. Полиморфизм клинических проявлений криоглобулинемического васкулита, ассоциированного с хроническим гепатитом С. Альманах клинической медицины. 2014;30:46-51.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis. 2008;3:25. doi:10.1186/1750-1172-3-25</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63(6):1748-1757. doi:10.1002/art.30319</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Gragnani L. Fognani E, Piluso A, Boldrini B, Urraro T, Fabbrizzi A, Stasi C, Ranieri J, Monti M, Arena U, Iannacone C, Laffi G, Zignego AL Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.Hepatology. 2015;61(4):1145-1153. doi:10.1002/hep.27623</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Dаmmacco F. Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, Mariggiт MA, Chironna M, Sansonno D. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343-353. doi:10.1182/blood-2009-10-245878</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Мухин Н.А., Козловская Л.В., Милованова Л.Ю., Тэгай С.В., Гордовская Н.Б., Игнатова Т.М., Кудлинский И.С. HCV-ассоциированный криоглобулинемический васкулит с тяжелым поражением почек и развитием В-клеточной лимфомы. Современные возможности изменения прогноза с помощью моноклональных антител к CD20 и противовирусной терапии Клиническая нефрология. 2011;2:61-69.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab? Ann Rheum Dis. 2014;73(9):e58. doi:10.1136/annrheumdis-2014-205997</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Saadoun D Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppéré B, Blanc F, Musset L, Piette JC, Rosenzwajg M, Cacoub P. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326-334. doi:10.1182/blood-2009-10-248518</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Terrier ВSaadoun D, Sène D, Sellam J, Pérard L, Coppéré B, Karras A, Blanc F, Buchler M, Plaisier E, Ghillani P, Rosenzwajg M, Cacoub P. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum. 2009;60(8):2531-2540. doi:10.1002/art.24703</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Visentini M, Tinelli C, Colantuono S, Monti M, Ludovisi S, Gragnani L, Mitrevski M, Ranieri J, Fognani E, Piluso A, Granata M, De Silvestri A, Scotti V, Mondelli MU, Zignego AL, Fiorilli M, Casato M. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. Autoimmunity Revi. 2015;14(10):889-896. doi:10.1016/j.autrev.2015.05.013</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y, Franceschi S, Talamini R, Holly EA, Grulich AE, Cerhan JR, Hartge P, Cozen W, Boffetta P, Brennan P, Maynadiй M, Cocco P, Bosch R, Foretova L, Staines A, Becker N, Nieters A.. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol. 2008;6(4):451-458. doi:10.1016/j.cgh.2008.02.011</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A, Pietrogrande M, Renoldi P, Bombardieri S, Bordin G. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM. 1995;88(2):115-126.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F, Sansonno D. Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection: a 15-year prospective study. Medicine (Baltimore). 2013;92(5): 245-256. doi:10.1097/MD.0b013e31829d2abc</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011;117(6):1792-1798. doi:10.1182/blood-2010-06-275818</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Kumada H. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120(12):1034-1041. doi: 10.1016/j.amjmed.2007.06.022</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>De Re V, Caggiari L, Simula MP, De Vita S, Mazzaro C, Lenzi M, Massimo GM, Monti G, Ferri C, Zignego AL, Gabrielli A, Sansonno D, Dammacco F, Libra M, Sacchi N, Talamini R, Spina M, Tirelli U, Cannizzaro R, Dolcetti R. Role of the HLA class II: HCV-related disorders. Ann New York Academy of Sciences. 2007;1107:308-318. doi:10.1196/annals.1381.033</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Fognani E, Giannini C, Piluso A, Gragnani L, Monti M, Caini P, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia. PLoS One. 2013;8(5):e62965. doi:10.1371/journal.pone.0062965</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Lenzi M, Johnson PJ, McFarlane IG, Ballardini G, Smith HM, McFarlane BM, Bridger C, Vergani D, Bianchi FB, Williams R. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet. 1991;338(8762):277-280. doi: 10.1016/0140-6736(91)90418-O</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology. 2003;125:1723-1732. doi: 10.1053/j.gastro.2003.09.025</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010-2017. doi:10.1001/jama.297.18.2010</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology. 2012;55(2):634-641. doi:10.1002/hep.25499</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Paydas S. Hepatitis C virus and lymphoma. Critical Rev Oncol/Hematol. 2015;93(3):246-56. doi:10.1016/j.critrevonc.2014.10.008</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, Marrocchi ME, Di Pietro E, La Villa G, Laffi G, Gentilini P. Prevalence of bcl-2 rearrangement in patients with hepatitis C virusrelated mixed cryoglobulinemia with or without B-cell lymphomas. Ann Int Med. 2002;137(7):571-580. doi:10.7326/0003-4819-137-7-200210010-00008</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Forghieri F, Luppi M, Barozzi P, Maffei R, Potenza L, Narni F, Marasca R. Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. Clin Development Immunol. 2012;2012:1-9. doi:10.1155/2012/807351</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59(1):169-177. doi:10.1016/j.jhep.2013.03.018</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with nonhepatitis C virus-related mixed cryoglobulinemia. Arch Int Med. 2006;166(19):2101-2108. doi:10.1001/archinte.166.19.2101</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum. 2006;54(11):3696-3706. doi:10.1002/art.22168</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Hermine O, Lefrиre F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. New Engl J Med. 2002;347(4):89-94. doi:10.1056/NEJMoa013376</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Mazzaro C, De Re V, Spina M, Dal Maso L, Festini G, Comar C, Tirelli U, Pozzato G. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol. 2009;145(2):255-257. doi:10.1111/j.1365-2141.2008.07565.x</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d’Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404-1410. doi:10.1093/annonc/mdu166</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C, Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Béral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C. ANRS HC-13 Lympho-C Study Group Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol. 2015;90:197-203. doi:10.1002/ajh.23889</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>La Mura V, De Renzo A, Perna F, D’Agostino D, Masarone M, Romano M, Bruno S, Torella R, Persico M.. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma. J Hepatol. 2008;49(4):557-563. doi:10.1016/j.jhep.2008.06.025</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Digest Dis Scie. 2015;60(12):3801-3813. doi:10.1007/s10620-015-3801-y</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>McGuire BM, Julian BA, Bynon JS, Cook WJ, King SJ, Curtis JJ, Accortt NA, Eckhoff DE. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Int Med. 2006;144(10):735-741. doi:10.7326/0003-4819-144-10-200605160-00007</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Fabrizi F, Martin P, Cacoub P, Messa P, Donato FM. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother. 2015;16(12):1815-1827. doi:10.1517/14656566.2015.1066333</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Ozkok A, Yildiz A. Hepatitis c virus associated glomerulopathies. World J Gastroenterol. 2014;20(24):7544-7554. doi:10.3748/wjg.v20.i24.7544</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2008;109:1-99. doi:10.1038/ki.2008.81</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Kasuno K, Ono T, Matsumori A, Nogaki F, Kusano H, Watanabe H, Yodoi J, Muso E. Hepatitis C virus-associated tubulointerstitial injury. Am J Kidney Dis. 2003;41(4):767-775. doi: 10.1016/S0272-6386(03)00024-6</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36(6):1439-1445. doi:10.1053/jhep.2002.37191</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Society Nephrol. 2009;4(1):207-220. doi:10.2215/CJN.03710708</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10(3):415-423. doi:10.1007/s12072-015-9684-3</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Appel GB. Membranoprolferative glomerulonephritis — mechanisms and treatment. Contributions Nephrol. 2013;181:163-174. doi:10.1159/000348635</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nature Rev Nephrol. 2015;11(1):14-22. doi:10.1038/nrneph.2014.217</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kobayashi M, Kobayashi M, Kumada H. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Int Med. 1998;37(10):836-840. doi:10.2169/internalmedicine.37.836</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Ji F, Li Z, Ge H, Deng H. Successful interferon-б treatment in a patient with IgA nephropathy associated with hepatitis C virus infection. Int Med. 2010;49(22):2531-2532. doi:10.2169/internalmedicine.49.4365</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Dey AK, Bhattacharya A, Majumdar A. Hepatitis C as a potential cause of IgA nephropathy. Indian J Nephrol. 2013;23(2):143-145. doi:10.4103/0971-4065.109443</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Morales JM, Pascual-Capdevila J, Campistol JM, Fernandez-Zatarain G, Muñoz MA, Andres A, Praga M, Martinez MA, Usera G, Fuertes A, Oppenheimer F, Artal P, Darnell A, Rodicio JL. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation. 1997;63(11):1634-1639. doi:10.1097/00007890-199706150-00017</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Cheng Z, Zhou B, Shi X, Zhang Y, Zhang L, Chen L, Liu X. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chinese Med J (Engl). 2014;127(7):1206-1210.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Stehman-Breen C, Alpers C, Fleet W, Fleet WP, Johnson RJ. Focal segmental sclerosis among patients infected with HCV. Nephron. 1999;81(1):37-40. doi:10.1159/000045243</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Guerra G, Narayan G, Rennke HG, Jaber BL. Crescentic fibrillary glomerulonephritis associated with hepatitis C viral infection. Clin Nephrol. 2003;60:364-368. doi:10.5414/CNP60364</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Fabrizi F, Bruchfeld A, Mangano S, Dixit V, Messa P, Martin P. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int J Artificial Organs. 2007;30(3):212-219. doi:10.1111/j.1365-2893.2007.00907.x</mixed-citation></ref></ref-list></back></article>
